Wellness company Medifast (NYSE:MED) reported Q3 2026 results topping the market’s revenue expectations, but sales fell by 19.4% year on year to $72.05 million. Guidance for next quarter’s revenue was better than expected at $65 million at the midpoint, 1.4% above analysts’ estimates. Its GAAP loss of $1.57 per share was significantly below analysts’ consensus estimates.
Is now the time to buy MED? Find out in our full research report (it’s free for active Edge members).
Medifast (MED) Q3 2026 highlights:
- Revenue $72.05 million vs S&P analysts’ estimates of $71.3 million (19.4% year-on-year decline, 1% beat)
- EPS (GAAP) -$1.57 vs analyst estimates of -$0.35 (significant miss)
- Revenue guidance $65 million at the midpoint for Q4 2026, above analyst estimates of $64.1 million
- GAAP EPS guidance $0.13 at the midpoint for Q4 2026, beating analyst estimates by 204%
- EBITDA guidance $12 million at the midpoint for the full year, above analyst estimates of $4.4 million
- Operating margin -26.9%, down from -4.6% in the same quarter last year
- Market capitalization $125.2 million
StockStory’s take
Medifast’s third quarter results were marked by a positive market response, as the company’s revenue slightly exceeded Wall Street’s expectations despite a substantial year-over-year decline. Management attributed the performance to the successful rollout of the Trilogy brand and related products, which have begun to gain traction among coaches and clients. CEO Nicholas Johnson emphasized that improvements in coach productivity and engagement, alongside investments in new training and compensation systems, have helped stabilize the business amid ongoing shifts in the weight management and metabolic health markets. Johnson noted, “Coach productivity improved year over year for the fourth consecutive quarter, to 54% in Q3 and grew an estimated 8% sequentially.”
Looking forward, Medifast’s guidance is shaped by an ongoing focus on profitability and operational efficiency as the company transitions further into metabolic health. Management’s expectations for growth are centered on continued adoption of the Trilogy system, further rollout of new products, and ongoing cost discipline through initiatives like Project Catalyst. CEO Nicholas Johnson highlighted that the company aims to leverage its new platform to gain share in the broader metabolic health market, stating, “We believe these trends leave us well positioned to deliver profitability in the fourth quarter.” CFO James Maloney added that advances in automation and artificial intelligence are expected to drive further SG&A efficiencies, supporting margin improvement as the business scales.
Key insights from management’s remarks
Management pointed to the Trilogy brand launch, enhanced coach training, and operational streamlining as primary contributors to the quarter’s performance and evolving business model.
-
Trilogy brand launch: The introduction of Trilogy, Medifast’s new metabolic health brand, marked a major step in repositioning the company beyond traditional weight loss. Management reported strong initial engagement from coaches, with 95% of active earning coaches in September offering Trilogy Reset products to clients.
-
Coach productivity gains: Despite a declining number of active earning coaches, average revenue per coach rose 54% year over year. The company credits its new compensation structure and unified training system, Trilogy Business Blueprint, for incentivizing higher productivity and focusing coach efforts on scalable business activities.
-
Shift in client conversations: With the increased prevalence of GLP-1 medications for weight loss, Medifast’s coaches are emphasizing not just total weight lost but the preservation of lean mass and metabolic health. Management sees this as a differentiator as the market moves toward holistic health outcomes.
-
Operational efficiency drive: Project Catalyst, Medifast’s cost realignment initiative, included facility closures, IT application reductions, and workforce adjustments. Management indicated that these actions are expected to accelerate the path to profitability while retaining the ability to scale as the business returns to growth.
-
AI integration and process improvements: Management discussed the growing use of artificial intelligence across the business, including in process automation and coach tools. CFO James Maloney expects these investments to drive ongoing SG&A efficiencies and provide operating leverage as the company grows.
Drivers of future performance
Medifast’s outlook for the coming quarters depends on the success of its new brand and products, ongoing cost reductions, and adapting to industry changes.
-
Adoption of Trilogy system: Management believes that broader uptake of the Trilogy metabolic health system—especially the Reset, Refine, and Renew phases—will be key to driving client engagement and supporting future revenue growth as the company moves beyond weight loss.
-
Operational leverage from cost actions: Continued execution of Project Catalyst and further process improvements, including AI-driven automation, are expected to allow Medifast to maintain lower fixed costs and improve margins even as sales volumes change.
-
Navigating GLP-1 competition: The company sees the rise of GLP-1 weight loss medications as both a challenge and an opportunity, aiming to position its coaching and products as complementary for clients seeking sustainable health rather than short-term results. Management warned that the total number of active earning coaches may remain below last year’s levels in the near term, but expects productivity per coach to offset some of this decline.
Catalysts in upcoming quarters
In the upcoming quarters, StockStory analysts will track (1) the pace of adoption and retention for Trilogy system products and related client engagement, (2) further improvements in coach productivity and stabilization or growth in the active coach base, and (3) measurable cost efficiencies from Project Catalyst and AI integration. Progress in these areas will be crucial for Medifast’s path to sustainable profitability and market share gains in the metabolic health category.
Medifast currently trades at $12.10, up from $11.85 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).
Our favorite stocks right now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.